share_log

Here's What To Make Of Surgery Partners' (NASDAQ:SGRY) Decelerating Rates Of Return

Here's What To Make Of Surgery Partners' (NASDAQ:SGRY) Decelerating Rates Of Return

以下是对Surgery Partners(纳斯达克股票代码:SGRY)收益率下降的解释。
Simply Wall St ·  07/05 10:23

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. However, after investigating Surgery Partners (NASDAQ:SGRY), we don't think it's current trends fit the mold of a multi-bagger.

你知道有一些财务指标可以为潜在的多袋人提供线索吗?在一个完美的世界中,我们希望看到一家公司向其业务投入更多资本,理想情况下,从这些资本中获得的回报也在增加。基本上,这意味着公司拥有可以继续进行再投资的盈利计划,这是复合机器的特征。但是,在调查了Surgery Partners(纳斯达克股票代码:SGRY)之后,我们认为目前的趋势不符合多袋机的模式。

What Is Return On Capital Employed (ROCE)?

什么是资本使用回报率(ROCE)?

For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Surgery Partners:

对于那些不知道的人,投资回报率是衡量公司相对于业务所用资本的年度税前利润(其回报)的指标。分析师使用以下公式来计算外科合作伙伴:

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)

已动用资本回报率 = 息税前收益 (EBIT) ¥(总资产-流动负债)

0.068 = US$436m ÷ (US$7.0b - US$523m) (Based on the trailing twelve months to March 2024).

0.068 = 4.36亿美元 ÷(70亿美元-5.23亿美元) (基于截至2024年3月的过去十二个月)

So, Surgery Partners has an ROCE of 6.8%. In absolute terms, that's a low return and it also under-performs the Healthcare industry average of 11%.

因此,Surgery Partners的投资回报率为6.8%。从绝对值来看,回报率很低,也低于医疗保健行业11%的平均水平。

roce
NasdaqGS:SGRY Return on Capital Employed July 5th 2024
纳斯达克GS:SGRY 2024年7月5日动用资本回报率

In the above chart we have measured Surgery Partners' prior ROCE against its prior performance, but the future is arguably more important. If you're interested, you can view the analysts predictions in our free analyst report for Surgery Partners .

在上图中,我们将Surgery Partners之前的投资回报率与之前的表现进行了比较,但可以说,未来更为重要。如果您有兴趣,可以在我们为外科合作伙伴提供的免费分析师报告中查看分析师的预测。

What Can We Tell From Surgery Partners' ROCE Trend?

我们可以从手术伙伴的投资回报率趋势中得出什么?

There are better returns on capital out there than what we're seeing at Surgery Partners. Over the past five years, ROCE has remained relatively flat at around 6.8% and the business has deployed 43% more capital into its operations. Given the company has increased the amount of capital employed, it appears the investments that have been made simply don't provide a high return on capital.

那里的资本回报比我们在Surgery Partners看到的要好。在过去的五年中,投资回报率一直相对持平,约为6.8%,该业务在运营中投入的资金增加了43%。鉴于该公司增加了动用资本金额,看来已经进行的投资根本无法提供很高的资本回报率。

The Bottom Line

底线

As we've seen above, Surgery Partners' returns on capital haven't increased but it is reinvesting in the business. Investors must think there's better things to come because the stock has knocked it out of the park, delivering a 195% gain to shareholders who have held over the last five years. Ultimately, if the underlying trends persist, we wouldn't hold our breath on it being a multi-bagger going forward.

正如我们在上面看到的那样,Surgery Partners的资本回报率没有增加,但它正在对业务进行再投资。投资者一定认为会有更好的事情发生,因为该股已经脱颖而出,为在过去五年中持股的股东带来了195%的收益。归根结底,如果潜在的趋势持续下去,我们就不会屏住呼吸了,因为它是未来的 “多管齐下”。

Since virtually every company faces some risks, it's worth knowing what they are, and we've spotted 3 warning signs for Surgery Partners (of which 1 makes us a bit uncomfortable!) that you should know about.

由于几乎每家公司都面临一些风险,因此值得了解它们是什么,我们已经为外科合作伙伴发现了3个警告信号(其中1个让我们有点不舒服!)你应该知道的。

If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.

如果你想寻找收益丰厚的稳健公司,可以免费查看这份资产负债表良好且股本回报率可观的公司名单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,发送电子邮件至 editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发